Storia in 5 fonti

FDA expert panel recommends against approval of Capricor’s Duchenne drug

STAT is live-blogging an FDA meeting on Capricor Therapeutics’ treatment for Duchenne muscular dystrophy, which has been the subject of a contentious regulatory review.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo17 h fa

FDA expert panel recommends against approval of Capricor’s Duchenne drug

STAT is live-blogging an FDA meeting on Capricor Therapeutics’ treatment for Duchenne muscular dystrophy, which has been the subject of a contentious regulatory review.

originale

Timeline cronologica

lunedì 27 luglio 2026·statnews.com
Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug
Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.
lunedì 27 luglio 2026·benzinga.com
Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics
FDA briefing documents question Capricor's deramiocel efficacy in DMD, while the company defends its trial analysis ahead of July 29.

FDA expert panel recommends against approval of Capricor’s Duchenne drug

Confronto fonti

FDA expert panel recommends against approval of Capricor’s Duchenne drug

Timeline cronologica

Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

Capricor shares plunge after FDA says DMD therapy lacks efficacy ahead of adcomm

Capricor Duchenne cell therapy voted down by FDA panel

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

FDA Committee Votes Down Duchenne Drug

Capricor shares plunge after FDA says DMD therapy lacks efficacy ahead of adcomm

Capricor Duchenne cell therapy voted down by FDA panel

FDA expert committee reviews Capricor Therapeutics’ Duchenne drug

FDA expert panel recommends against approval of Capricor’s Duchenne drug

FDA Committee Votes Down Duchenne Drug

FDA and Capricor clash over deramiocel efficacy data at Duchenne adcomm vote